Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taxol clinical sponsorship

Executive Summary

HHS is offering a Cooperative Research and Development Agreement (CRADA) to a pharmaceutical manufacturer to "effectively pursue the clinical development" of taxol as an anticancer agent. The National Cancer Institute currently has a two-year supply of taxol for use in clinical trials. In return for providing funding to NCI for the clinical work and collection of raw materials, the pharmaceutical company will receive exclusive rights to the source data from Phase III clinical trials. Isolated from the bark of the Western Yew tree, taxol is believed to have some efficacy in treating ovarian cancer. For further information, contact Dale Shoemaker, NCI, 301/496-7912.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS016091

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel